Ovarian cancer diagnostic test

Proteome Systems has announced a collaboration with Prince Henry's Institute Medical Research (PHIMR) to combine their IP and expertise in ovarian cancer for the discovery and development of novel diagnostic markers.

Proteome Systems has discovered and patented novel markers for epithelial ovarian cancer using its proprietary proteomic and glycoproteomic technology platforms. The company is actively seeking partnerships with academic and clinical groups with expertise in ovarian cancer to further expand its portfolio of ovarian cancer markers and clinically evaluate these for the development of a diagnostic test.

Associate Professor David Robertson leads the team at PHIMR that has previously developed a test to diagnose ovarian cancer. The test is useful for initial diagnosis and monitoring recurrence of the disease in post-menopausal women, but it does not have the required specificity and sensitivity for application to diagnosis of early state disease. Consequently, there is a need to identify new diagnostic markers for the development of a highly sensitive test for early stage ovarian cancer. PHIMR bring complementary technology in proteomics and reproductive biology, as well as clinical expertise in ovarian cancer, for the discovery and evaluation of new diagnostic markers.